Adrien Sipos, M.D., Ph.D.

Equibles does not estimate personal net worth.

Get an email with a short summary when Q32 Bio Inc. publishes a filing, an earnings call transcript or a press release.

About Adrien Sipos, M.D., Ph.D.

Q32 Bio Inc. reported in an 8-K filed June 25, 2025 that Adrien Sipos, M.D., Ph.D. was appointed Interim Chief Medical Officer, effective July 9, 2025. Q32 Bio Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Q32 Bio Inc. includes Albert Seymour, Ph.D. (CEO and Board Member), Jodie Morrison (CEO and Board Member), Paul G. Alloway, Ph.D. (CEO and COO) and 7 others.

“Adrien Sipos, M.D., Ph.D. has been appointed by the Company as its Interim Chief Medical Officer, effective as of July 9, 2025.”

Q32 Bio Inc. Form 8-K, filed June 25, 2025 · Read the filing

Affiliation history

Q32 Bio Inc. (QTTB)
SEC 8-K

Current
2025-07-09–present

Company network

Q32 Bio Inc.

QTTB

Current role

Biotechnology · Healthcare

Leadership on record at Q32 Bio Inc.

Albert Seymour, Ph.D. CEO, Board Member
Jodie Morrison CEO, Board Member
Paul G. Alloway, Ph.D. CEO, COO
Tim Kelly CEO, COO
Arthur O. Tzianabos, Ph.D. Chairman
Mark Iwicki Chairman
Charles Michaud, Jr. CFO, Chief Accounting Officer
Lee Kalowski CFO
Arthur Tzianabos Board Member
Bill Lundberg Board Member

Recent activity

Executive change Appointed: Interim Chief Medical Officer Q32 Bio Inc. (QTTB)
2025-07-09